Intravitreal Ranibizumab 0.5 mg Injection

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Phase 3

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

Active, not recruitingNCT04108156

Hoffmann-La RocheDiabetic Macular Edema

Start: 2019-09-30End: 2027-07-20Updated: 2026-07-10

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

CompletedNCT04503551

Hoffmann-La RocheDiabetic Retinopathy

Start: 2020-08-10End: 2026-02-23Updated: 2026-04-02

Related Papers

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.

2025-04-014 citations

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.

2025-04-013 citations

Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema

PLoS Genetics2023-08-167 citations

435-P: Port Delivery System with Ranibizumab (PDS) in Diabetic Retinopathy (DR) with or without Diabetic Macular Edema (DME)

Diabetes2021-06-01